Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Finished Goods (2019 - 2025)

Historic Finished Goods for CorMedix (CRMD) over the last 7 years, with Q3 2025 value amounting to $12.8 million.

  • CorMedix's Finished Goods rose 123321.92% to $12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.8 million, marking a year-over-year increase of 123321.92%. This contributed to the annual value of $3.0 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that CorMedix reported Finished Goods of $12.8 million as of Q3 2025, which was up 123321.92% from $3.3 million recorded in Q2 2025.
  • CorMedix's 5-year Finished Goods high stood at $12.8 million for Q3 2025, and its period low was $245668.0 during Q2 2021.
  • Its 3-year average for Finished Goods is $2.7 million, with a median of $1.1 million in 2024.
  • As far as peak fluctuations go, CorMedix's Finished Goods plummeted by 3978.7% in 2021, and later surged by 123321.92% in 2025.
  • Over the past 3 years, CorMedix's Finished Goods (Quarter) stood at $245668.0 in 2021, then skyrocketed by 1104.77% to $3.0 million in 2024, then surged by 333.05% to $12.8 million in 2025.
  • Its Finished Goods stands at $12.8 million for Q3 2025, versus $3.3 million for Q2 2025 and $2.1 million for Q1 2025.